ClinicalTrials.gg
CompletedNCT06382961Updated May 24, 2024

Postoperative Dexmedetomidine in Prevention of Postoperative Delirium

An interventional study of Dexmedetomidine injection and Sufentanil injection in Delirium in Old Age and Anesthesia; Adverse Effect, sponsored by Boston Intelligent Medical Research Center, Shenzhen United Scheme Technology Co., Ltd.. Completed at 1 site in China. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2024-05-24.

Sponsored by Boston Intelligent Medical Research Center, Shenzhen United Scheme Technology Co., Ltd. · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Nov 2023, registered Apr 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
287
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 78 studies testing dexmedetomidine in Delirium — 16 open to participants now, 18 under way, 4 of them phase 3. Dexmedetomidine · Delirium.

Enrollment
20th of 78
287 · median 98
Started
2023
with 4 others
No phase
19 of 78
5 open now
Registered
70th of 78
by date

Among the 78 studies testing dexmedetomidine in Delirium, this one is the 20th largest by enrollment, is one of 5 that started in 2023, is one of 19 with no phase, and was the 70th registered.

Delirium

933 studies on the registry are indexed under Delirium; 189 are open to participants now.

Browse Delirium studies →

Open to participants now

16 of the 78 studies testing dexmedetomidine in Delirium are open now, in 6 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 16 open studies →

About dexmedetomidine

Dexmedetomidine: first FDA approval 1999 (PRECEDEX), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 127 Delirium studies recruiting now, 99 (78%) set no upper age limit and 8 (6%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 78 studies testing dexmedetomidine in Delirium, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn how postoperative infusion of dexmedetomidine would influence postoperative delirium in elderly patients undergoing lung surgery. The main questions it aims to answer are :

  1. Does postoperative dexmedetomidine reduce the incidence of delirium after lung surgery?
  2. Does postoperative dexmedetomidine introduce other medical problems? Researchers will compare dexmedetomidine and sufentanil to see if dexmedetomidine works to reduce delirium.

Participants will undergo routine postoperative care:

  1. Patient-controlled self anesthesia with sufentanil only or combination of sufentanil and dexmedetomidine
  2. Postoperative visit twice a day for at least seven days
03

Conditions studied

  • Delirium in Old Age
  • Anesthesia; Adverse Effect

Browse trials for

04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • elective surgery for lobectomy or segmentectomy

Exclusion criteria

Exclusion Criteria:

  • local allergy to anesthetics;
  • patients with a clear preoperative history of nervous system and mental system diseases or long-term use of sedatives or antidepressants;
  • history of alcoholism, drug abuse or drug dependence;
  • have a history of brain surgery or injury;
  • epilepsy and associated mental and cognitive dysfunction, long-term stress stimulation, or psychological disorders;
  • sick sinus syndrome, second-degree or greater atrioventricular block or other for use of α2 adrenergic agonist;
  • liver and kidney insufficiency.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
287 participants (actual)

Study arms

  • Experimental
    Experiment

    Drug: Dexmedetomidine injection

  • Active comparator
    Control

    Drug: Sufentanil injection

Interventions

  • Combining with 3 μg.kg-1 sufentanil, 3 μg.kg-1 dexmedetomidine is injected through intravenous patient controlled anesthesia pump in a 2 ml bolus with 20 minutes lock-out, and a background infusion rate of 2 ml per hour.

  • 3 μg.kg-1 sufentanil is injected through intravenous patient controlled anesthesia pump in a 2 ml bolus with 20 minutes lock-out, and a background infusion rate of 2 ml per hour.

06

What researchers measure

Primary outcomes

  1. Incidence of postoperative delirium

    Time frame: Delirium is assessed at 8 am and 8 pm for 3 days after surgery

Secondary outcomes

  1. Incidence of postoperative nausea and vomiting

    Time frame: Assessed twice a day for 7days after surgery

  2. incidence of postoperative complications

    Other postoperative complications including including hypotension, hypertension, bradycardia, tachycardia, and hypoxemia

    Time frame: Assessed daily for 3 days after surgery

  3. Pain intensities

    patient pain assessed using numeric rating scale, ranged from 0 to 11, higher score indicate higher pain intensity

    Time frame: Assessed daily at 8 am for 3 days after surgery

07

Study locations

1 site
  • Kunming Children's Hospital
    Kunming, Yunnan 650100, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2023 to primary completion in Mar 2024, 3 months.

Of 222 interventional studies with no phase under Delirium, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 45. This study's 3 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2024
First posted
Apr 25, 2024
StartActual
Nov 11, 2023
Primary completionActual
Mar 6, 2024
CompletionActual
Apr 28, 2024
Last update
May 24, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06382961
Lead sponsor
Boston Intelligent Medical Research Center, Shenzhen United Scheme Technology Co., Ltd.
Collaborators
Shenzhen People's Hospital, Dongyuan People's Hospital, Kunming Children's Hospital
Responsible party
Sponsor
First posted
Apr 25, 2024
Start date
Nov 11, 2023
Primary completion
Mar 6, 2024
Completion
Apr 28, 2024
Last update
May 24, 2024

Study contacts

Rui Zhao
study director · Department of Anesthesiology, Kunming Children's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexmedetomidine

Start the discussion